Pas­cal So­ri­ot says 2020 ap­proval still pos­si­ble for As­traZeneca's Covid-19 vac­cine as the world awaits the safe­ty board­'s de­ci­sion

Mod­er­na was the first com­pa­ny to put a vac­cine can­di­date in­to hu­mans, but for much of the pan­dem­ic it was As­traZeneca and their aca­d­e­m­ic part­ners at Ox­ford Uni­ver­si­ty putting out the most ag­gres­sive time­lines. They signed deals with the UK promis­ing to sup­ply dos­es as ear­ly as Sep­tem­ber and Sarah Gilbert, the vac­cine’s aca­d­e­m­ic ar­chi­tect, talked, al­beit cau­tious­ly, about get­ting ef­fi­ca­cy da­ta by that time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA